Clifford Chance

Drug Pricing Check-up: A Debrief of the FTC and DOJ's First Joint Listening Session on Lowering Americans' Drug Prices Through Competition

July 3, 2025

On June 30, 2025, the U.S. Department of Justice's Antitrust Division (DOJ) and the Federal Trade Commission (FTC) jointly hosted one of three planned "listening sessions" on drug pricing, as mandated by President Trump's executive order, titled "Lowering Drug Prices by Once Again Putting Americans First." The session brought together government officials, patient advocates, academics, and industry representatives as panelists. The agencies framed the series as a hunt for purported "regulatory abuse" and "gamesmanship" that has the potential to impede generic or biosimilar competition. They will reconvene on July 24 for a panel titled, "Formulary and Benefit Practices and Regulatory Abuse Impacting Drug Competition," and will conclude on August 4 with a solutions-focused panel titled, "Turning Insights into Action to Reduce Drug Prices."

Download PDF